GSK To Downplay Europe Because of Poor Innovation Support, Focuses On Japan, U.S. Instead
This article was originally published in PharmAsia News
Executive Summary
GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products.
You may also be interested in...
Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market
Prestige Brands acquires GlaxoSmithKline’s BC and Goody’s analgesic brands as part of $660 million deal for 17 North American OTC lines, also including Beano gas treatment, FiberChoice supplement and Sominex sleep aid.
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
GlaxoSmithKline R&D Under Scrutiny In Bid For Fresh Funding
It's crunch time for GlaxoSmithKline PLC's 38 biotech-like R&D units, which are competing for further funding as they reach the end of their first three-year investment cycle.